Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.59 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.47 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.47 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.47 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.47 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
| ▸ | PEPD | P12955 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | GLI1 | P08151 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2343227 | 1.00 | EPHX1 (0.59) | EPHX1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1570434 | 0.93 | EPHX1 (0.67) | EPHX1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9800227 | 0.93 | EPHX1 (0.67) | EPHX1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL17205447 | 0.93 | EPHX1 (0.67) | EPHX1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13557474 | 0.93 | EPHX1 (0.67) | EPHX1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9800070 | 0.93 | EPHX1 (0.67) | EPHX1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL8411453 | 0.89 | PEPD (0.56) | EPHX1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7761683 | 0.89 | PEPD (0.56) | EPHX1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL8411456 | 0.89 | PEPD (0.56) | EPHX1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7761680 | 0.89 | PEPD (0.56) | EPHX1PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114213313-B | Preparation method of 1, 2-cyclopentanediimide | 内蒙古源宏精细化工有限公司 | 2023-11-14 | — | — | CN | claimed |
| CN-115232058-A | Synthesis method of gliclazide intermediate 1,2-cyclopentanedicarboxamide | 上海巽田科技股份有限公司 | 2022-10-25 | — | — | CN | claimed |
| CN-114213313-A | Preparation method of 1, 2-cyclopentadiimide | 内蒙古源宏精细化工有限公司 | 2022-03-22 | — | — | CN | claimed |
| CN-109206358-B | Synthesis method of 1, 2-cyclopentadiimide | 济南爱思医药科技有限公司 | 2021-10-29 | — | — | CN | claimed |
| CN-112851563-A | Synthesis process of N-amino-3-azabicyclo [3,3,0] octane hydrochloride | 安徽金鼎医药股份有限公司 | 2021-05-28 | — | — | CN | claimed |
| CN-112624958-A | Synthetic method of medical intermediate 1, 2-cyclopentadienimide | 安徽金鼎医药股份有限公司 | 2021-04-09 | — | — | CN | claimed |
| US-20260085034-A1 | N-(BENZHYDRYL)CYCLOALKYLCARBOXAMIDE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | HERCULES CAPITAL, INC., AS AGENT | 2026-03-26 | — | — | US | disclosed |
| EP-4587422-A1 | N-(BENZHYDRYL)CYCLOALKYLCARBOXAMIDE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| CN-118002062-A | Reaction device and method for producing 1, 2-cyclopentadiformyl imine | 浙江工业大学 | 2024-05-10 | — | — | CN | disclosed |
| WO-2024059661-A1 | N-(BENZHYDRYL)CYCLOALKYLCARBOXAMIDE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| CN-117510394-A | Preparation method of N-amino-3-azabicyclo [3, 0] octane hydrochloride | 内蒙古源宏精细化工有限公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-117510394-A | Preparation method of N-amino-3-azabicyclo [3, 0] octane hydrochloride | 内蒙古源宏精细化工有限公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-115232057-B | Synthesis method of gliclazide intermediate 3-azabicyclo [3.3.0] octane | 上海巽田科技股份有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-103183632-A | Purification method of 3-azabicyclo-octane hydrochloride | SHANDONG FANGMING PHARM GROUP | 2013-07-03 | — | — | CN | disclosed |
| CN-102850257-A | Preparation method of 1,2-cyclopentane dicarboximide | SHANDONG FANGMING PHARM GROUP | 2013-01-02 | — | — | CN | disclosed |
| CN-102850257-A | Preparation method of 1,2-cyclopentane dicarboximide | SHANDONG FANGMING PHARM GROUP | 2013-01-02 | — | — | CN | disclosed |
| CN-100424077-C | Cyclopentane1,2-diimide preparation method | TAIZHOU SIWEI CHEMICAL PLANT (CN) | 2008-10-08 | — | — | CN | disclosed |
| CN-1876636-A | Cyclopentane1,2-diimide preparation method | TAIZHOU SIWEI CHEMICAL PLANT (CN) | 2006-12-13 | — | — | CN | disclosed |
| EP-1087937-A1 | CYCLIC HYDROXAMIC ACIDS AS METALLOPROTEINASE INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065867-A1 | CYCLIC HYDROXAMIC ACIDS AS METALLOPROTEINASE INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085034-A1 | N-(BENZHYDRYL)CYCLOALKYLCARBOXAMIDE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | GYS2, GYS1, PYGL | EPHX1 2283/4885PSEN1 97/4885PSEN2 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.